Baillie Gifford & Co. Sells 1,195 Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Baillie Gifford & Co. lessened its holdings in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNAFree Report) by 0.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,357,386 shares of the company’s stock after selling 1,195 shares during the quarter. Baillie Gifford & Co. owned approximately 0.06% of Ginkgo Bioworks worth $32,970,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in DNA. PDT Partners LLC acquired a new position in Ginkgo Bioworks during the third quarter valued at approximately $1,199,000. Erste Asset Management GmbH acquired a new position in Ginkgo Bioworks during the third quarter valued at approximately $4,075,000. Jacobs Levy Equity Management Inc. acquired a new position in Ginkgo Bioworks during the third quarter valued at approximately $2,282,000. BNP Paribas Financial Markets acquired a new position in Ginkgo Bioworks during the third quarter valued at approximately $1,287,000. Finally, PFG Investments LLC acquired a new position in Ginkgo Bioworks during the third quarter valued at approximately $1,541,000. Institutional investors own 78.63% of the company’s stock.

Ginkgo Bioworks Stock Performance

Shares of DNA stock opened at $14.73 on Tuesday. Ginkgo Bioworks Holdings, Inc. has a 12 month low of $5.26 and a 12 month high of $64.40. The company’s 50 day moving average is $11.34. The firm has a market capitalization of $846.38 million, a P/E ratio of -1.13 and a beta of 1.16.

Ginkgo Bioworks Profile

(Free Report)

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.

Featured Articles

Want to see what other hedge funds are holding DNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ginkgo Bioworks Holdings, Inc. (NYSE:DNAFree Report).

Institutional Ownership by Quarter for Ginkgo Bioworks (NYSE:DNA)

Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.